H.C. Wainwright raised the firm’s price target on Protagonist Therapeutics (PTGX) to $117 from $80 and keeps a Buy rating on the shares. Given Protagonist’s “proven track record in drug development,” the firm assigned a probability of success of 15% for both PN-8047 and its IL-4R antagonist, and a probability of success of 10% for its obesity programs.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics: Advancing Multi-Asset Inflammation and Obesity Pipeline with Strong Cash Runway Supports Buy Rating
- Protagonist Therapeutics Highlights Diversified Pipeline and Partnerships
- Advancing, De-Risked Pipeline and Near-Term Regulatory Catalysts Underpin Protagonist Therapeutics Buy Rating
- Protagonist Therapeutics price target raised to $110 from $88 at Truist
- Takeda, Protagonist Therapeutics submit rusfertide new drug application to FDA